摘要
目的 :通过AgNOR技术 ,针对不同的乳腺癌患者在四组联合化疗方案中筛选出敏感的联合化疗方案 ,指导临床用药。方法 :将 5 4例乳腺癌组织标本分别加入含有CMF、CAD、CEF及ET联合化疗方案的培养基中进行培养 ,应用AgNOR技术检测出各组肿瘤细胞中嗜银蛋白含量 ,计算出各组联合化疗方案对被测患者的敏感顺序。结果 :5 4例乳腺癌患者对所测的四组联合化疗方案反映出不同的敏感程度 ,各组间无显著差异 ,ET联合化疗方案对已耐药的病例仍有较高的敏感性。结论 :应用AgNOR技术在各种联合化疗方案中筛选敏感方案 ,具有客观、临床相关性好、简单、快捷及人为因素小等优点 。
Objective:To screen the most sensitive one for breast cancer among four different combined chemotherapy protocols by AgNOR technique and to guide the clinical activity.Methods:Histospecimens of 54 cases of breast cancer were cultured in different mediums which contained CMF,CAD,CEF and ET chemotherapy protocols respectively,the sequence of the sensitivity of different chemotherapy protocols was available by assaying argentophil protein in different tumor cells using AgNOR technique.Results:Each of the 54 cases of breast cancer showed different sensitivity in the four different mediums,there was no significant difference among each protocol.ET protocol still had high sensitivity in drug resistant cases.Conclusion:Screenmore sensitive chemotherapy protocol by AgNOR technique deserves further try because of its objectivity,better clinical correlation,simplicity,quickness and little artificial factors.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2000年第8期604-606,共3页
Chinese Journal of Clinical Oncology
基金
辽宁省卫生厅科研基金
大连市科委科研基金资助
关键词
AGNOR技术
乳腺癌
联合用药
药敏试验
AgNOR technique Breast cancer Combined chemotherapy protocol Drug sensitive detection
